OPKO Health to Sell BioReference Lab Assets to Labcorp for $722 Million Plus Earnout
OPKO Health entered an asset purchase agreement to sell BioReference’s clinical and anatomic pathology lab testing assets to Labcorp for $722 million in cash at closing, subject to revenue-based adjustments, plus up to $150 million over up to ten years tied to 4Kscore sales.
OPKO Health has signed an Asset Purchase Agreement to sell BioReference’s clinical and anatomic pathology lab testing assets to Labcorp. The transaction provides for $722 million in cash at closing, subject to revenue-based adjustments, and up to $150 million in additional payments over up to ten years, tied to sales of the 4Ksco…